Insomnia: Neurobiology, Clinical Evaluation, and Evidence-Based Treatment Approaches for Sleep-Onset Difficulty

Insomnia is a disorder of impaired sleep initiation, maintenance, or early-morning awakening, occurring despite adequate opportunity for sleep and producing daytime impairment. Clinically, insomnia is distinguished from normal short-term sleep disturbance by duration (at least three nights per week for at least three months, in chronic cases), magnitude of distress, and measurable functional consequences such as fatigue, impaired attention, mood dysregulation, and reduced work or social performance. Insomnia commonly presents as sleep-onset difficulty (taking longer than desired to fall asleep), which aligns with complaints like “can’t sleep” or “don’t sleep.” Epidemiologically, insomnia affects a substantial proportion of adults and is frequently comorbid with anxiety disorders, depressive disorders, chronic pain, and cardiometabolic disease.

Mechanistically, insomnia is best conceptualized as a dysregulation of the sleep-wake system involving hyperarousal, altered circadian timing, and maladaptive behavioral conditioning. Hyperarousal refers to persistent physiological and cognitive activation—elevated sympathetic tone, increased cortical and autonomic activity, and intrusive worry about sleep. In models such as Spielman’s 3P (predisposing, precipitating, perpetuating) framework, predisposing factors (e.g., genetic vulnerability, temperament, sex hormones, aging), precipitating events (stress, illness, medication changes), and perpetuating factors (conditioned arousal, sleep-related anxiety, irregular schedules) maintain the disorder even after the initial trigger resolves. At the neurobiological level, dysregulated inhibitory signaling, altered GABAergic function, hypocretin/orexin pathways influencing wakefulness, and changes in cortical networks that govern attentional control can contribute to increased sleep latency and fragmented sleep.

A clinical evaluation starts with a detailed sleep history: sleep onset latency, nocturnal awakenings, total sleep time, chronotype, sleep schedule regularity, caffeine/alcohol intake, nicotine use, exercise timing, napping, and exposure to screens or light at night. Daytime consequences must be documented, including concentration deficits, sleepiness, irritability, reduced motivation, and mood symptoms. The clinician should assess for comorbid sleep disorders, especially obstructive sleep apnea (loud snoring, witnessed apneas, morning headaches), restless legs syndrome (urge to move legs with uncomfortable sensations worse at rest), circadian rhythm sleep-wake disorders (delayed sleep phase, irregular sleep), and parasomnias. Medication and substance review is essential because insomnia may be secondary to agents such as stimulants, corticosteroids, some antidepressants, decongestants, and excessive alcohol use.

Objective testing is not routinely required for uncomplicated chronic insomnia, but it may be warranted when the diagnosis is uncertain, symptoms suggest another disorder, or treatments fail. Polysomnography can evaluate sleep-disordered breathing and periodic limb movements; actigraphy and sleep diaries can clarify circadian misalignment and quantify sleep timing. Standardized instruments such as the Insomnia Severity Index can help track symptom burden and treatment response.

First-line treatment is cognitive behavioral therapy for insomnia (CBT-I), which addresses perpetuating mechanisms through multiple components: stimulus control (using the bed only for sleep and sex, leaving the bed after a set period if unable to fall asleep), sleep restriction therapy (temporarily limiting time in bed to consolidate sleep, then gradually expanding), cognitive restructuring (reducing catastrophic beliefs and performance anxiety about sleep), and relaxation training. These interventions reduce conditioned arousal and interrupt the cognitive cycle of monitoring sleep. Evidence supports CBT-I as effective for chronic insomnia and as comparable or superior to pharmacotherapy for long-term outcomes.

Pharmacologic therapy may be considered for short-term relief or as a bridge while CBT-I takes effect, with careful attention to adverse effects, dependence risk, falls, and next-day impairment. Options include non-benzodiazepine hypnotics, melatonin receptor agonists, and orexin receptor antagonists; medication choice should reflect patient comorbidities, age, driving risk, and drug-drug interaction potential. Long-term use of many hypnotics is generally discouraged without reassessment because tolerance, rebound insomnia, and dependency can occur.

Adjunctive strategies include improving sleep hygiene (consistent wake time, minimizing bright light and stimulating content before bed, limiting caffeine after midday, and avoiding heavy late meals), managing comorbid depression or anxiety with evidence-based therapies, and treating underlying medical causes such as pain, reflux, or restless legs syndrome. In patients with circadian misalignment, timed light exposure and melatonin (appropriately dosed and timed) may be more effective than generic sleep hygiene alone.

If insomnia is persistent, clinically significant, or associated with panic symptoms, suicidal ideation, or severe functional impairment, prompt referral is recommended. The prognosis is favorable when perpetuating behaviors are addressed: sustained behavioral change and circadian stabilization often lead to reduced sleep latency and fewer awakenings. Source: [@sedenerbay]